Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 3.2% – Here’s What Happened

Posted by Francis Steltz on May 20th, 2026

Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report)’s stock price traded down 3.2% during mid-day trading on Monday . The stock traded as low as $0.6902 and last traded at $0.6973. 124,948 shares were traded during trading, a decline of 58% from the average session volume of 297,608 shares. The stock had previously closed at $0.7206.

Analyst Upgrades and Downgrades

Several research firms recently commented on ENLV. HC Wainwright boosted their price objective on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enlivex Therapeutics has a consensus rating of “Hold” and a consensus target price of $16.50.

View Our Latest Report on ENLV

Enlivex Therapeutics Stock Performance

The firm’s 50-day moving average is $0.91 and its 200 day moving average is $0.96. The firm has a market capitalization of $167.00 million, a PE ratio of -1.28 and a beta of 1.49.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ENLV. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares in the last quarter. HRT Financial LP lifted its holdings in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after purchasing an additional 135,198 shares in the last quarter. Jane Street Group LLC boosted its position in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. Invesco Ltd. acquired a new stake in Enlivex Therapeutics during the fourth quarter worth approximately $43,000. Finally, Susquehanna International Group LLP acquired a new stake in Enlivex Therapeutics during the third quarter worth approximately $57,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.